Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Samsung Biologics | Seoul | Healthcare | Pharmaceuticals | ₩68.83T | 64.8x | 0 | ₩965,000 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.4% Upside | Upgrade to Pro+ | |
Alteogen | KOSDAQ | Healthcare | Pharmaceuticals | ₩17.32T | -4,450.9x | 32.14 | ₩318,000 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.3% Upside | Upgrade to Pro+ | |
Yuhan | Seoul | Healthcare | Pharmaceuticals | ₩9T | 57x | 0.55 | ₩106,000 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Yuhan | Seoul | Healthcare | Pharmaceuticals | ₩9T | 57x | 0.55 | ₩117,700 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.6% Upside | Upgrade to Pro+ | |
Sk Biopharma | Seoul | Healthcare | Pharmaceuticals | ₩8.19T | 140.6x | 0.84 | ₩103,300 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.4% Upside | Upgrade to Pro+ | |
SK Bioscience Co | Seoul | Healthcare | Pharmaceuticals | ₩3.9T | -84.6x | 0.44 | ₩48,650 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2% Downside | Upgrade to Pro+ | |
Hanmi Pharm Co | Seoul | Healthcare | Pharmaceuticals | ₩3.55T | 22.1x | 0.96 | ₩273,500 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hugel | KOSDAQ | Healthcare | Pharmaceuticals | ₩2.85T | 26.1x | 0.33 | ₩261,000 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.3% Upside | Upgrade to Pro+ | |
Celltrion Pharm | KOSDAQ | Healthcare | Pharmaceuticals | ₩2.39T | 84x | ₩56,700 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Sam Chun Dang Pharm | KOSDAQ | Healthcare | Pharmaceuticals | ₩2.37T | 459.2x | 0.48 | ₩97,300 | -4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pharma Reaserch Products | KOSDAQ | Healthcare | Pharmaceuticals | ₩2.28T | 27.2x | 0.46 | ₩215,500 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.9% Upside | Upgrade to Pro+ | |
Hanmi Science | Seoul | Healthcare | Pharmaceuticals | ₩2.21T | 21.2x | 11.3 | ₩31,250 | -4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hanall Biopharma | Seoul | Healthcare | Pharmaceuticals | ₩1.89T | -282.1x | 1.42 | ₩35,750 | -4.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.7% Upside | Upgrade to Pro+ | |
ST Pharm | KOSDAQ | Healthcare | Pharmaceuticals | ₩1.81T | 52.1x | 0.31 | ₩87,300 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43% Upside | Upgrade to Pro+ | |
GC Biopharma | Seoul | Healthcare | Pharmaceuticals | ₩1.76T | -86.1x | 0.08 | ₩150,600 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.5% Upside | Upgrade to Pro+ | |
Daewoong Pharma | Seoul | Healthcare | Pharmaceuticals | ₩1.48T | 14.3x | 0.11 | ₩124,300 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nature Cell | KOSDAQ | Healthcare | Pharmaceuticals | ₩1.42T | -287.2x | 0.4 | ₩23,050 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HLB Life Science | KOSDAQ | Healthcare | Pharmaceuticals | ₩1.21T | 15.2x | 0.09 | ₩9,980 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Caregen | KOSDAQ | Healthcare | Pharmaceuticals | ₩1.21T | 33.9x | -7.78 | ₩24,500 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -43.9% Downside | Upgrade to Pro+ | |
Chong Kun Dang Pharma | Seoul | Healthcare | Pharmaceuticals | ₩1.2T | 6.3x | 0.16 | ₩91,500 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HK Inno.N | KOSDAQ | Healthcare | Pharmaceuticals | ₩1.09T | 26.1x | ₩37,450 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Oscotec | KOSDAQ | Healthcare | Pharmaceuticals | ₩914.81B | -190.5x | -2.56 | ₩23,350 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mezzion Pharma | KOSDAQ | Healthcare | Pharmaceuticals | ₩898.9B | -62.7x | -1.4 | ₩29,850 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Daewoong | Seoul | Healthcare | Pharmaceuticals | ₩885.28B | 7x | 2.96 | ₩21,200 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.2% Upside | Upgrade to Pro+ | |
Medy-Tox | KOSDAQ | Healthcare | Pharmaceuticals | ₩869.01B | 81.7x | 5.48 | ₩124,000 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HLB Therapeutics | KOSDAQ | Healthcare | Pharmaceuticals | ₩845.91B | -28.4x | 0.11 | ₩10,180 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dongkook Pharmaceutical | KOSDAQ | Healthcare | Pharmaceuticals | ₩734.71B | 12x | 0.4 | ₩16,430 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.3% Upside | Upgrade to Pro+ | |
Green Cross Holdings | Seoul | Healthcare | Pharmaceuticals | ₩724.35B | -10.3x | 0.01 | ₩24,050 | -8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Green Cross | Seoul | Healthcare | Pharmaceuticals | ₩724.35B | -10.3x | 0.01 | ₩15,480 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Boryung Pharm | Seoul | Healthcare | Pharmaceuticals | ₩671.17B | 10.8x | 0.09 | ₩10,180 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.9% Upside | Upgrade to Pro+ |